|
|||||
|
|
A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III |
|
| Authors: | Andrew G. Chapple Peter F. Thall |
| Abstract: | |
| Keywords: | Bayesian design Clinical trial dose finding phase I‐II clinical trial phase III clinical trial |